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surgical treatment for stress urinary
incontinence in women: cost-effectiveness
and value of information analyses in the
context of a mixed methods feasibility
study
Tara Homer1*, Jing Shen1, Luke Vale1, Elaine McColl2, Douglas G. Tincello3, Paul Hilton2,4 and on behalf of the
INVESTIGATE-I studies groupAbstract
Background: INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic
Effect?) was a mixed methods study to assess the feasibility of a future randomised controlled trial of invasive urodynamic
testing (IUT) prior to surgery for stress urinary incontinence (SUI) in women. Here we report one of the study’s five
components, with the specific objectives of (i) exploring the cost-effectiveness of IUT compared with clinical assessment
plus non-invasive tests (henceforth described as ‘IUT’ and ‘no IUT’ respectively) in women with SUI or stress-predominant
mixed urinary incontinence (MUI) prior to surgery, and (ii) determining the expected net gain (ENG) from additional
research.
Methods: Study participants were women with SUI or stress-predominant MUI who had failed to respond to
conservative treatments recruited from seven UK urogynaecology and female urology units. They were
randomised to receive either ‘IUT’ or ‘no IUT’ before undergoing further treatment. Data from 218 women
were used in the economic analysis. Cost utility, net benefit and value of information (VoI) analyses were performed
within a randomised controlled pilot trial. Costs and quality-adjusted life years (QALYs) were estimated over 6 months
to determine the incremental cost per QALY of ‘IUT’ compared to ‘no IUT’. Net monetary benefit informed the VoI
analysis. The VoI estimated the ENG and optimal sample size for a future definitive trial.
Results: At 6 months, the mean difference in total average cost was £138 (p = 0.071) in favour of ‘IUT’; there was no
difference in QALYs estimated from the SF-12 (difference 0.004; p = 0.425) and EQ-5D-3L (difference − 0.004; p = 0.725);
therefore, the probability of IUT being cost-effective remains uncertain. The estimated ENG was positive for further
research to address this uncertainty with an optimal sample size of 404 women.
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Conclusions: This is the largest economic evaluation of IUT. On average, up to 6 months after treatment, ‘IUT’ may be
cost-saving compared to ‘no IUT’ because of the reduction in surgery following invasive investigation. However,
uncertainty remains over the probability of ‘IUT’ being considered cost-effective, especially in the longer term. The VoI
analysis indicated that further research would be of value.
Trial registration: ISRCTN. ISRCTN71327395. Registered 7 June 2010.
Keywords: Randomised controlled pilot trial, Feasibility study, Cost-effectiveness, Value of information, Invasive
urodynamic testing, Stress urinary incontinenceBackground
Urinary incontinence (UI) affects 25–45% of women
aged 15 years and older [1]. The most prevalent types
are stress urinary incontinence (SUI) and stress-
predominant mixed urinary incontinence (MUI), which
jointly account for 65–85% of cases [2].
Current National Institute for Health and Care
Excellence (NICE) guidelines state that cystometry is not
required prior to conservative treatments or surgery
when a diagnosis of SUI is likely on clinical grounds (i.e.
where there are no symptoms of over active bladder or
voiding dysfunction, no anterior compartment prolapse,
and no previous surgery for SUI) [3, 4].
A number of previous studies have considered the use
of invasive urodynamic testing (IUT) in determining the
optimum treatment strategy for SUI [5–8]. However,
differences in inclusion criteria and methods used mean
that there is continuing uncertainty over the current
position of IUT in the diagnostic pathway of SUI [9, 10].
IUT use in the UK varies; a 2002 survey of gynaecology
and urology units performing IUT found that only half
had a guideline on the indications for its use and 85%
performed cystometry, the most commonly used form of
IUT, in all women with UI [11].
The continuing uncertainty over the clinical utility of
urodynamic investigation resulted in calls for further
high-quality primary research from major UK and
international bodies [12–15]. As a result, the UK
National Institute for Health Research – Health
Technology Assessment programme (NIHR-HTA)
commissioned a mixed methods feasibility study (IN-
VESTIGATE-I), including an external pilot randomised
controlled trial, in order to clarify how best to address
this uncertainty [16]. Given the limited evidence on the
cost-effectiveness of IUT [15], an economic evaluation
was incorporated in the INVESTIGATE-I study. This
study is the first to concurrently estimate the clinical
and cost-effectiveness of IUT in this population [5, 8].
The economic evaluation included cost utility, net
monetary benefit (NMB) and value of information
(VoI) analyses. The aims of the economic components,
reported here, were to inform an economic analysis for
a future definitive clinical trial and to estimate thesample size required to achieve a definitive answer on
the cost-effectiveness of IUT.
Methods
The INVESTIGATE-I randomised controlled pilot trial
was undertaken in seven centres across the UK. Full
details of inclusion and exclusion citeria, other aspects
of the study design, and clinical effectiveness outcomes
are reported elsewhere [16–18].
Participants randomised within INVESTIGATE-I had
a clinical diagnosis of SUI or stress-predominant MUI
and were about to undergo surgical treatment. The aim
of the study was to evaluate whether IUT, compared
with basic clinical assessment and non-invasive tests,
altered treatment decisions and outcomes in women
suitable for surgical treatment. The treatments provided
as part of the study included surgical and non-surgical
treatments. Participants had a 6 month follow-up period
and both costs and utilities were the primary outcomes
for the economic evaluation. Treatment costs, including
information on IUT, were collected via a case report
form (CRF) completed by clinical staff during the
woman’s initial treatment phase. Follow-up resource use
was collected via a self-completed Participant Costs
Questionnaire completed at 6 months. Data on utilities
were based on responses to the self-completed SF-12
and EQ-5D-3L administered at baseline and 6 months.
Further information on the estimation of costs and
utilities is provided under “Estimation of costs” and
“Estimation of effects”.
Between April 2011 and December 2012, 771 women
were assessed for eligibility, and of these, 110 were ran-
domised to the control arm (‘no IUT’) and 112 to the
intervention arm (‘IUT’). The economic evaluation was
conducted from the perspective of the UK National
Health Service (NHS).
Estimation of costs
Healthcare resource use and costs were estimated for all
women using data collected within the trial and from
routine sources [19, 20]. Resource use and costs were
categorised as those used prior to treatment, to deter-
mine the optimum treatment strategy (i.e. the costs of
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surgery and alternative non-surgical treatments), and
those incurred after treatment (i.e. other healthcare re-
sources used over a 6 month period following the start
of treatment). We assumed non-invasive investigations
would be similar across both arms and hence excluded
these from our analysis. There may be an argument for
reporting the investigation costs prior to treatment sep-
arately from those incurred by and after treatment.
However, since the former are of necessity different
(favouring ‘no IUT’), it is our view that the cost of the
total package of care (before, during and after treatment)
is the more relevant outcome.
Resources and costs prior to treatment
The cost of IUT was estimated using a micro-costing
approach [21], which provides a more accurate estima-
tion of costs than a ‘top-down’ approach [21, 22]. Data
on resource use of the investigation are presented in
Additional file 1, so that readers can judge the appli-
cability to their own circumstances. Although conven-
tional dual-channel subtracted cystometry with
simultaneous pressure/flow voiding studies (henceforth
abbreviated to ‘cystometry’), videourodynamics and am-
bulatory urodynamics were all permitted within the
study protocol, only cystometry was costed as it was
performed in 92% of women randomised to ‘IUT’. Thus,
if any IUT was undertaken, the cost of cystometry was
used. The consumable resources used in cystometry
were obtained from clinical staff at one participating site
(Liz Dixon, personal communication, July 2013). The
cost of the primary staff member who performed the
investigation was based on information, collected via a
CRF, on the length of time in the consulting room and
staff grade. Based on clinical advice, we judged that a
nurse (UK band 5) would also be present for the IUT, so
this cost was included in the ‘IUT’ cost. Salary costs
were obtained from routine sources [20].
Resources and costs required to provide treatment
The expected treatment for those randomised to ‘no
IUT’ was surgery. The initial treatment for women ran-
domised to ‘IUT’ was based on the findings from investi-
gation and could include surgical and non-surgical
approaches. The cost of surgery was taken from the
NHS reference cost [19] for ‘vaginal tape operations for
urinary incontinence’. All non-surgical treatments: be-
haviour modification, bladder retraining, and pelvic floor
muscle training, were micro-costed based on personal
communication and NHS guidelines [3] with further de-
tails provided in Additional file 1. Five women deferred
initial treatment and were classified as ‘watchful waiting’;
it was assumed they would still use containment prod-
ucts provided by the NHS. This cost was obtained froma recent HTA on non-surgical management of SUI, [23]
inflated to 2015 prices [24].
Resource use and costs of services used after treatment
The Patient Costs Questionnaire, completed 6 months
after surgery or the start of non-surgical treatment,
asked about women’s use of primary and secondary care
services following initial treatment. Primary care costs
included visits to the general practitioner (GP), practice
nurse, continence nurse, community physiotherapist and
prescriptions. Costs of prescription were estimated from
a routine source [20] assuming a standard GP prescrip-
tion charge. Secondary care included inpatient and out-
patient visits and their costs also came from a routine
source [19].
Estimation of effects
Quality-adjusted life years (QALYs) were estimated using
the area under the curve approach [25] for every
woman, based on responses to the SF-12 and EQ-5D-3L
completed at baseline and 6 months. Both the SF-12
and the EQ-5D-3L are widely used in the measure-
ment of health-related quality of life and are applicable
to a wide range of health conditions and treatments
[26, 27]. Multiple imputation [21] was used to estimate
missing QALY values, controlling for randomised allo-
cation and age. We assumed missing data were miss-
ing at random [22].
Economic evaluation
The cost-utility analysis used an intention-to-treat
principle. Results were presented as point estimates of
the mean incremental costs, QALYs and cost per QALY,
estimated using both the trial data (unadjusted analysis)
and seemingly unrelated regression (SUR) [28]. The SUR
analysis is considered to be more reliable as it improves
precision surrounding cost-effectiveness estimates [29].
SUR permits the simultaneous estimation of costs and
QALYs, calculated at an individual level, while account-
ing for unobserved individual characteristics that could
affect both costs and QALYs and lead to potential cor-
relation between these two variables [29]. Both equations
controlled for randomised allocation to estimate the
difference in costs and QALYs between the two arms.
The QALY equation also controlled for baseline utility
and age as these can cause an imbalance in the QALY
estimate [30]. An intervention is typically deemed cost-
effective when the incremental cost-effectiveness ratio
(ICER) is less than £20,000 per QALY gained [31].
Sensitivity analysis
A stochastic sensitivity analysis, using the bootstrapping
technique [32], explored the impact of the statistical im-
precision surrounding estimates of costs, effects and
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effectiveness ratio was presented on the cost-effectiveness
plane [33]. Confidence intervals and p values were esti-
mated by the SUR model to identify any statistically sig-
nificant difference in costs and effects. Other uncertainties
addressed using sensitivity analyses are presented else-
where [16]. Due to the short follow-up period, costs and
QALYs were not discounted.
Net monetary benefit
The NMB was calculated at the widely used UK
willingness-to-pay (WTP) threshold of £20,000 [31]. The
WTP threshold is the opportunity cost of reallocating
resources for one additional QALY. This allows conver-
sion of health benefits (QALYs) into a common metric
of pounds sterling by multiplying QALYs by WTP (see
equation below). NMB allows us to make comparisons
among multiple treatments as well as enabling the VoI
analysis. Confidence intervals were estimated from the
bootstrapped results.
NMB ¼ λΔE−ΔC½ 
where λ is the willingness-to-pay threshold; Δ is the
difference between the two randomised arms (‘IUT’ and
‘no IUT)’; E is the effects; and C is the costs.
Value of information
The expected value of sampling information (EVSI) [34]
method was used to predict the costs and benefits of
obtaining further information based on current informa-
tion. The EVSI model was estimated by imputing the
trial data in to the mathematical derivations and equa-
tions presented by Willan and Pinto [34]. The principle
underpinning EVSI is that the allocation of funds for
research to reduce clinical and economic uncertainties
has financial and opportunity costs. The financial cost is
the total cost incurred from conducting further research.
The opportunity cost is the delay in making and imple-
menting recommendations on the use of IUT, caused by
undertaking additional research.
EVSI determines the expected net gain (ENG) from
future research, i.e. that the expected added value of
further research minus the (financial and opportunity)
costs of that research. A positive ENG indicates that the
added value of additional research exceeds the costs.
EVSI also enables the prediction of the economically
and statistically efficient sample size in each randomised
arm of a future economic evaluation as part of a rando-
mised controlled trial. This sample size was then dou-
bled to account for a two-arm trial and inflated to
account for dropouts—in this case, the rate of non-
response to the SF-12 and EQ-5D-3L questionnaires.
The optimal sample size in this context is the totalnumber of complete cases that would maximise the
ENG and provides a definitive economic answer on the
use of IUT.
The economic evaluation was conducted in Stata using
the seemingly unrelated regression command sureg
(StataCorp LLC, Texas, USA). The VoI analysis was per-
formed using EXCEL and further details are available
from the lead author on request.Results
There were 222 women initially randomised in
INVESTIGATE-I. Information on 218 women was used
in the economic analysis; 110 in the ‘IUT’ arm and 108
in the ‘no IUT’ arm. Four women were excluded due to
the following: withdrawal (n = 2), ineligibility (n = 1) and
an error in the participant’s unique identifier (n = 1).Costs
In terms of initial treatment, 74% of women underwent
surgery in the ‘IUT’ arm compared to 94% of women in
the ‘no IUT’ arm (Fisher’s exact p < 0.01). There were no
other statistically significant differences in healthcare re-
sources used during the follow-up period between the
two arms (Additional file 2). There was a difference of
£138 (95% CI − £288, £12; p = 0.071), in average total
cost per woman between trial arms (Table 1), driven by
the lower number of women undergoing surgical treat-
ment in the ‘IUT’ arm. The difference in costs suggests
that IUT has the potential to be cost-saving, although as
a pilot study, our trial was not powered to achieve statis-
tical significance on this or other outcomes.Effects
QALY values could only be estimated for women who
completed the SF-12 or EQ-5D-3L at both baseline and
6 months (Additional file 3). The response rates to both
questionnaires were relatively low with QALYs being
estimated for only half of the participants having both
baseline and 6 month utility data. The uncertainty
caused by the dropout rate was incorporated into the
analyses. The uncertainty surrounding estimates of costs,
effects and overall cost-effectiveness are presented in the
cost-effectiveness plane. A complete case analysis was
also performed and found similar results [16]. The SF-12
SUR results, presented in Table 1, slightly favoured ‘IUT’
(diff 0.004; 95% CI − 0.006, 0.013: p = 0.425) whereas the
EQ-5D-3L SUR results slightly favoured ‘no IUT’ (diff −
0.004; 95% CI − 0.024, 0.016: p = 0.725). However, both
differences were close to zero, and neither were statisti-
cally significant, indicating that there is no evidence of a
difference in benefits in terms of QALYs.
Table 1 Cost-effectiveness results
Investigation
strategy
Total avg. cost
per woman (£)
Incremental cost (£) Total avg. QALYs
per woman
Incremental QALYs ICER (£) Probability that IUT is
cost-effective for different
threshold values for society’s
willingness to pay for a QALY
SF-12 results £0 K £10 K £20 K £30 K £50 K
‘no IUT’ 1489 0.377 0.04 0.03 0.05 0.09 0.12
‘IUT’ 1351 − 138 0.385 0.008 Dominant 0.96 0.97 0.95 0.91 0.88
‘no IUT’
adjusteda
0.04 0.03 0.04 0.07 0.1
‘IUT’ adjusteda − 138 0.004 Dominant 0.96 0.97 0.96 0.93 0.9
EQ-5D-3L results
‘no IUT’ 1489 0.413 0.018 7667 0.97 0.80 0.60 0.51 0.43
‘IUT’ 1351 − 138 0.395 0.03 0.20 0.40 0.49 0.57
‘no IUT’ adjusteda 0.004 34,500 0.96 0.84 0.64 0.54 0.46
‘IUT’ adjusteda − 138 0.04 0.16 0.36 0.46 0.54
aResults reported from SUR estimation; adjusting for randomisation in the cost equation and for randomisation, baseline utility (estimated from both the SF12 and
EQ-5D-3L respectively), and age in the HRQoL equation
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We estimated the ICER, using QALY estimates derived
from both the SF-12 and EQ-5D-3L, using unadjusted and
SUR analyses (Table 1). Using the SF-12 results, ‘IUT’ was
the dominant investigation strategy as it was more effect-
ive and less costly (albeit the differences in costs and ef-
fects were not statistically significant). Based on the EQ-
5D-3L results, ‘no IUT’ generated more benefits than ‘IUT’
but it was also more costly; hence, an ICER was derived in
order to judge the preferred investigation strategy. The
value of the ICER varied markedly between the unadjusted
and SUR analyses, ‘no IUT’, with an ICER of £34,500,
would not be considered cost-effective in the adjusted
analysis at current WTP thresholds [31].
The economic evaluation results are useful for deter-
mining the balance of probabilities which can help to
inform decision makers. The balance of probabilities is
the probability of IUT being considered cost-effective at
different WTP values (Table 1). Using the SF-12 results,
IUT was the investigation strategy with the higher
probability of being cost-effective at all WTP values up
to and including £30,000 [31].
Sensitivity analysis
Stochastic sensitivity analyses were performed to test the
robustness of the results. The imprecision surrounding
these estimates is shown on the cost-effectiveness plane
(Figs. 1 and 2). The majority of iterations for both results
were in the southern quadrants, supporting the sugges-
tion of cost savings associated with IUT. In Fig. 1
(derived from the SF-12), the average of the boot-
strapped iterations was in the south-east quadrant,
highlighting that on average IUT was more effective interms of both costs and QALYs. In Fig. 2 (derived from
the EQ-5D-3L), the average of the bootstrapped itera-
tions was positioned in the south-west quadrant suggest-
ing that whilst IUT, on average, was less costly it was
also less effective in terms of QALYs. In both figures, the
average bootstrapped iteration lies close to the y-axis
emphasising that there was no significant difference in
effects.
Net monetary benefit
We imputed the unadjusted SF-12 cost-effectiveness
results into the NMB equation. The NMB was £160
(95% CI £144, £235) in favour of ‘IUT’. The unadjusted
EQ-5D-3L cost-effectiveness results were used in a sen-
sitivity analysis.
Value of information analysis
The assumption for the EVSI, based on the NMB
results, was to estimate the additional value of future
research to determine whether ‘IUT’ was cost-effective
compared to ‘no IUT’. The parameters used and the
results of the EVSI model are presented in
Additional file 4 and Fig. 3 respectively.
The results estimated from the EVSI model suggest
there is additional value of £30m to be gained from
further research to determine whether ‘IUT’ is cost-
effective compared to ‘no IUT’ in investigating women
with SUI and stress-predominant MUI prior to surgical
treatment. The financial (£1.8m) and opportunity
(£8.9m) costs of further research were subtracted from
the EVSI to estimate the ENG (£19m). The optimal sam-
ple size was estimated as 91 women randomised to each
arm; after inflation for non-responses to the SF-12
Fig. 1 Incremental cost-utility scatterplot derived from the SF-12 data
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in total. If achieved, in a future definitive trial, this sam-
ple size would maximise ENG and should result in a
definitive conclusion on the cost-effectiveness of IUT.
Sensitivity analysis
Sensitivity analysis was performed to determine the
impact on ENG and optimal sample size when we
imputed the unadjusted EQ-5D-3L cost-effectiveness
results. The NMB based on the EQ-5D-3L unadjusted
cost-effectiveness results was £216 (95% CI − £197,
£269) in favour of ‘no IUT’; hence, the assumption for
the EVSI was to estimate the additional value of future
research to determine whether ‘no IUT’ was cost-
effective compared to ‘IUT’. It is important to note that
this difference in the assumption was driven by the
increased QALYs experienced by ‘no IUT’.Fig. 2 Incremental cost-utility scatterplot derived from the EQ-5D-3L dataThe results estimated from the EVSI model, presented
in Additional file 5, suggest there is additional value of
£61m to be gained from further research. The optimal
sample size was estimated as 103 women randomised to
each arm; after inflation for non-responses to the EQ-
5D-3L questionnaires, the optimal sample size was 416
women (note the SF-12 and EQ-5D-3L had different
response rates and were inflated accordingly). The
sample size required to maximise society’s ENG was
relatively consistent when we imputed the EQ-5D-3L
and SF-12 results (416 women vs. 404 women).
Discussion
It must be emphasised that INVESTIGATE-I was
planned as a mixed methods feasibility study with the
primary objective of informing the decision whether or
not to proceed to a definitive randomised comparative
Fig. 3 Expected value of sampling information derived from SF-12 data
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or conduct of such a trial are warranted; hence, the pilot
trial within the INVESTIGATE-I package was not pow-
ered to provide definitive answers to either clinical or
economic outcomes. It follows that the VoI analysis
builds upon an inherently ‘underpowered economic
evaluation’, with the aim of establishing how large an
adequately powered definitive study would need to be.
Despite its limited statistical power, the pilot trial
undertaken within the INVESTIGATE-I package re-
mains one of the largest studies undertaken addressing
the clinical utility of IUT in SUI and stress-predominant
MUI, and the largest to consider cost-effectiveness [15].
During the planning of INVESTIGATE-I, two other tri-
als were identified as ongoing, and both have since been
published [5, 8]. Although the protocols were rather
different, both employed a non-inferiority design and
reported no benefit from IUT. Both of these earlier stud-
ies included women with SUI or stress-predominant
MUI, but in contrast to INVESTIGATE-I, both also re-
quired that urine leakage on stress should be clinically
demonstrated. It has long been recognised that patients
with predominant symptoms of SUI who also have clin-
ically demonstrable stress leakage are very likely (97%)
to have urodynamic stress incontinence on invasive
testing [35], and some clinical guidelines have followed
this evidence base [36, 37]. Our intention in the feasibi-
lity study INVESTIGATE-I was to broaden the inclusion
criteria, to include those in whom stress leakage was not
necessarily clinically demonstrated, so that we might
potentially influence policy and practice for a greater
number of women following a future definitive trial.
In a model-based economic evaluation in women with
overactive bladder and/or urge-predominant MUI, it was
found that IUT was cost-effective only in women withurge-predominant MUI and that women with overactive
bladder symptoms should receive treatment on the basis
of the clinical diagnosis [38, 39]. The question of how
much different is the cost-effectiveness of IUT in women
with SUI only compared to women with stress-
predominant MUI is therefore pertinent. Although we
have not undertaken such a sub-group analysis in this
feasibility study, it could usefully be incorporated into a
future definitive trial.
It has been argued on the basis of systematic review
and meta-analysis that comprehensive clinical assess-
ment is a sufficient investigation in the diagnosis of SUI
or stress-predominant MUI without voiding difficulties,
as long as the women undergo careful office evaluation
[40]. In contrast, Serati et al. found that, even in women
with a preliminary categorisation of ‘uncomplicated SUI’,
the additional information provided from invasive inves-
tigation can alter treatment [41]; they did not however
provide data on the outcomes from treatment. In
INVESTIGATE-I, there was a 20% reduction (p < 0.01)
in surgical treatment in the ‘IUT’ arm suggesting that
IUT provided additional information which influenced
treatment decisions. In addition, only a small number of
women report pure symptoms of SUI and hence satisfy
current NICE criteria for undergoing clinical assessment
only [42]. Whilst we would therefore concur that IUT
influences treatment, the issue of how far it affects treat-
ment outcome remains unresolved.
In previous work, it has been implied that there would
be cost-savings associated with omitting IUT from the
diagnostic pathway of SUI and stress-predominant MUI;
however, there is no evidence to support this conclusion
as the studies included in the meta-analysis provided no
information on cost-effectiveness [40]. Our results do
not support this assumption as cost-savings (mean diff
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strapped 95% CI (− £258, £12) does include 0 but the
upper end of the CI, which would favour ‘no IUT’, is
close to zero, and possibly of no economic significance
as less than 1% of the bootstrapped iterations would
support there being cost-savings from ‘no IUT’. Perhaps
the more appropriate interpretation of these results is
that for one in five women there is a potential cost-
saving of £1244 from the IUT strategy as a result of
avoiding surgical treatment. These cost-savings would be
reduced by the costs of the investigation (IUT) itself and
subsequent non-surgical treatments prescribed as a con-
sequence. However, given that non-surgical treatments
are relatively low cost compared to surgery, it is antici-
pated that cost-savings would still result. It must be
emphasised that INVESTIGATE-I was a pilot study and
the economic analyses were not powered to determine
whether these cost-savings were statistically significant.
Nevertheless, possible additional costs are small and of
questionable economic significance.
Both unadjusted and adjusted analyses were performed
as part of the economic analysis. The importance of
using SUR to adjust for potential imbalances in the trial
data, due to individual characteristics, which could influ-
ence costs and effects is widely recognised [29]. The
implications of not adjusting for these imbalances could
result in the differences in outcomes being overesti-
mated and hence could result in policy-makers being
misinformed. In both of our analyses, the estimated
incremental cost difference remained consistent; how-
ever, the unadjusted analysis overestimated the incre-
mental difference in QALYs, particularly the EQ-5D-3L
results. This difference in QALYs has affected the ICER
in that ‘no IUT’ would be considered cost-effective in
the unadjusted analysis but not the adjusted analysis at
current willingness-to-pay thresholds [31]. For a future
definitive study, we would recommend the use of both
analyses to estimate costs and effects as this would
reduce any potential uncertainty around the probability
of IUT being considered cost-effective.
It is acknowledged that there is a large amount of
missing data in these analyses, with less than 50% of
patients returning completed questionnaires at both
baseline and 6 months, 48% had QALYs estimated from
the EQ-5D-3L and 45% from the SF-12. Although the
uncertainty caused by the dropout rate is incorporated
into the analyses, the need for caution in interpretation
is clear, particularly since somewhat more data were
missing from the intervention than control arms [16].
Potential solutions to increase the response rates are
presented elsewhere [16].
The difference in the utility scores estimated from the
EQ-5D-3L and SF-12 is not surprising as they both
capture different dimensions to estimate quality of lifeand have different recall periods; the EQ-5D-3L asks
participants to measure their health today and the SF-12
asks participants to recall their health over the last
4 weeks [43]. In the case of INVESTIGATE-I, the SF-12
is arguably more sensitive to changes in UI and has been
shown to be more responsive than the EQ-5D for
capturing changes in less chronic conditions [44]. That
being said, going forward, the EQ-5D is recommended
by NICE [31] and the introduction of the EQ-5D-5L has
increased the sensitivity of the questionnaire [45]. In
addition, the response rate to the EQ-5D tends to be
higher [43], which was also evident from this study;
hence, the EQ-5D-5L should be considered as the pre-
ferred economic outcome measure in a future study.
To our knowledge, this is the first full economic evalu-
ation comparing IUT with basic clinical assessment to
basic clinical assessment alone in the investigation of
SUI and stress-predominant MUI in women prior to
surgical treatment, albeit in the context of a feasibility
study. As previously mentioned, the advantage of includ-
ing IUT in the investigation of SUI and stress-
predominant MUI in women prior to surgical treatment
is that women would receive treatment tailored to their
diagnosis and potentially avoid unnecessary surgery [41].
This could generate cost-savings as non-surgical treat-
ments are relatively low cost compared to surgical treat-
ment. Although performing IUT could change the
diagnosis or treatment, it does not necessarily mean that
the woman’s quality of life improves (this is supported
by the QALY results and the results of the Value of
Urodynamic Evaluation (ValUE) trial) [5]. Longer-term
data are needed to identify whether women experience
any changes in outcomes over time and whether the
cost-savings associated with IUT are maintained in the
long term. If a woman who has avoided surgical treat-
ment on the basis of IUT continues with non-surgical
treatment in the long term, then cost-savings may be
maintained. If, on the other hand, she does not benefit
from conservatism, and later goes on to have surgical
treatment, then clearly no savings will have been made,
and indeed additional costs will accrue. Within
INVESTIGATE-I, no patients went on to have surgery
after initial non-surgical management, perhaps because
of the short time horizon of the pilot; in a definitive trial,
we would recommend that a minimum 12 month
follow-up be considered.
Norton et al. performed a cost simulation on the
results of the ValUE trial as a secondary analysis to
determine the costs associated with urodynamic studies
(UDS) [46]. They concluded that millions of dollars
could be saved in the USA by omitting preoperative
UDS in women with uncomplicated stress-predominant
urinary incontinence prior to surgical treatment [46].
However, given their inclusion criteria, this is
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UDS underwent surgical treatment (94.6%) [5]. Their
conclusions should not be generalised outside of their
patient group and the USA, hence are not applicable to
our population.
Where our data are useful is in the judgement of
whether further research to address the uncertainty in
the results would be valuable. The VoI analysis suggests
that there is added value (at least £19 million for the UK
alone) to be gained from additional research. It is
reassuring that despite the lack of statistical significance
surrounding our results, a conclusion can be drawn that
there are potential cost-savings associated with IUT and
additional value to be gained from further research. The
primary clinical outcome used in the INVESTIGATE-I
pilot trial was the International Consultation on Incon-
tinence Modular Questionnaire (ICIQ) Female Lower
Urinary Tract Symptoms (ICIQ-FLUTS) total score.
There is consistency in the sample size calculations esti-
mated from the standard statistical criteria looking for a
minimum clinical difference of 3 points in ICIQ-FLUTS
score (n = 410) [16] and the EVSI results for both the
SF-12 (n = 404) and EQ-5D-3L (n = 416). Using all three
estimations to determine the sample size of a future
definitive trial means the trial will be powered to deter-
mine both the clinical and economic effectiveness of
IUT. This combination of approaches is rarely per-
formed and is consistent with recent recommendations
on sample size determination [47].
As with any sample size calculation, there are uncer-
tainties [48]. In the case of sample sizes based on the
EVSI results, one uncertainty is around the methodo-
logical approach to estimate cost-effectiveness. Arguably,
the better method is to estimate cost-effectiveness based
on the SUR approach and hence base estimates of the
EVSI on these results. This was not possible as not all of
the required data were available. Had it been possible,
we would expect the estimated sample size to be slightly
higher.
Although it is an overused conclusion in clinical
research and reviews, we can say with some certainty
that there is additional value to be gained from future
research to evaluate the clinical and cost-effectiveness of
IUT in the investigation of SUI and stress-predominant
MUI in women prior to surgical treatment. Future stud-
ies should consider expanding the time horizon beyond
6 months to determine the long-term benefits associated
with surgical and non-surgical treatment options, in-
corporate the woman’s perspective in the economic
evaluation and, if using similar outcome measures,
should consider using the sample size estimates deter-
mined in the current VoI analysis and previously pub-
lished conventional power calculations [16]. The
combination of our economic results with the economicresults of a future definitive trial should result in suffi-
cient evidence to inform NICE or other policy making
organisations internationally in making recommenda-
tions on the value of IUT in the diagnostic pathway of
SUI and stress-predominant MUI [49].
Conclusion
This is the first full economic evaluation of IUT in diag-
nosing SUI or stress-predominant MUI in women whom
stress leakage was not necessarily clinically demon-
strated, albeit in the context of a feasibility study. Our
findings suggest that IUT may be cost-saving compared
to basic clinical assessment and non-invasive tests in the
investigation of SUI and stress-predominant MUI prior
to surgical treatment, assessed over the short term.
There is additional net value to be gained from further
research in this area and the question should be ad-
dressed by a trial that is both appropriately powered to
detect clinical and economic differences between IUT
and basic clinical assessment, and extended over a longer
time scale. A sample size of 404–416 randomised women
should be capable of providing definitive answers to these
questions.
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